학술논문
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Document Type
Article
Author
Valle, J.W.; Vogel, A.; Denlinger, C.S.; He, A.R.; Bai, L.-Y.; Orlova, R.; Van Cutsem, E.; Adeva, J.; Chen, L.-T.; Obermannova, R.; Ettrich, T.J.; Chen, J.-S.; Wasan, H.; Girvan, A.C.; Zhang, W.; Liu, J.; Tang, C.; Ebert, P.J.; Aggarwal, A.; McNeely, S.C.; Moser, B.A.; Walgren, R.A.; Oliveira, J.M.; Carlesi, R.; Oh, D.-Y.
Source
In: The Lancet Oncology . (The Lancet Oncology, October 2021, 22(10):1468-1482)
Subject
Language
English
ISSN
14745488
14702045
14702045